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Abstract 
 
Objective: Earlier studies have reported the influence of subchondral bone osteoblasts 
(SBOs) on phenotypical changes of articular cartilage chondrocytes (ACCs) during 
osteoarthritis (OA) development. The molecular mechanisms involved during this 
process still remain elusive, in particular the signal transduction pathways. The aim of 
this study was to investigate in vitro effects of OA SBOs on the normal ACCs 
phenotypical changes, and to unveil the potential involvement of mitogen activated 
protein kinase (MAPK) signaling pathways during this process.  
Methods: Normal and arthritic cartilage and bone samples were collected for the 
isolation of ACCs and SBOs. Direct and indirect co-culture models were applied to 
study chondrocyte hypertrophy under the influence of OA SBOs. Mitogen-activated 
protein kinases in the regulation of the cell-cell interactions were monitored by 
phosphorylated antibodies and relevant inhibitors.  
Results: Our results showed that OA SBOs lead to increased hypertrophic gene 
expression and matrix calcification in ACCs by means of both direct and indirect cell-
cell interactions.  For the first time, we demonstrated that OA SBOs suppressed p38 
phosphorylation and induced ERK1/2 signal phosphorylation in co-cultured ACCs. 
The ERK1/2 pathway inhibitor, PD98059, significantly attenuated hypertrophic 
changes induced by conditioned media from OA SBOs and the p38 inhibitor, 
SB203580, resulted in the upregulation of hypertrophic genes in ACCs. 
Conclusion: This study suggests that the pathological interaction of OA SBOs and 
ACCs is mediated via the activation of ERK1/2 phosphorylation and deactivation of 
p38 phosphorylation, resulting in ACCs undergoing hypertrophic differentiation.  
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Introduction 
Explanations as to the aetiology of osteoarthritis (OA) has long focussed on the 
destruction of articular cartilage, the activating factors of which were thought to be 
triggered as a result of repetitive loading (1, 2). Cartilage pathology in OA is 
associated with changes of cellular phenotype of articular chondrocytes to a state of 
terminal differentiation (3, 4). However, the long term molecular events that are 
responsible for this transition are not well understood.  
Recent studies suggest that the subchondral bone plays a major role in OA cartilage 
changes, an indication of active communication taking place between the subchondral 
bone and the cartilage in the progression of OA (5, 6). Bone anabolic factors, such as 
osteocalcin (OC), osteopontin (OPN), and alkaline phosphatase (ALP) are all 
upregulated in OA subchondral bone osteoblasts (SBOs) compared to normal SBOs 
supporting the notion of dysfunction of osteoblast behaviour (7-9). It has been shown 
in OA animal models that a thickening of subchondral bone precedes cartilage 
changes (10, 11), and it has further been demonstrated that in vivo factors produced by 
OA SBOs increase glycosaminoglycan (GAG) release from the cartilage (12)  and can 
influence cartilage specific gene expression (13). It was demonstrated by the 
application of a co-culture model of bovine explant subchondral bone and cartilage, 
that excision of subchondral bone from articular cartilage resulted in increased 
chondrocytes death, thus demonstrating the important role of subchondral bone in 
maintaining joint homeostasis (14). However, the molecular mechanisms, and in 
particular signaling pathways, by which normal and OA SBOs regulate articular 
cartilage phenotype remain unknown.  
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Activation of the three major classes of mitogen activated protein kinases (MAPKs) - 
extracellular signal–regulated kinase (ERK1/2), c-Jun N-terminal kinase (JNK) and 
p38 MAPK - has been detected in chondrocytes (15). MAPKs are known to be 
responsible for the conversion of vast number of extracellular stimuli into specific 
cellular responses, including chondrocyte proliferation and differentiation (16, 17). 
The requirement of MAPK signaling pathways, in particular p38 and ERK1/2, during 
various phases of endochondral ossification has also been demonstrated in several 
studies (18, 19). MAPK signaling pathway has been shown to play a distinct role in 
aspects of cartilage biology such as cartilage matrix synthesis and homeostasis (20, 
21). The role of MAPK signaling in skeletal development and in the biology of 
cartilage, points towards a possible association of altered MAPK signaling and OA. 
Indeed, alterations in these signaling pathways are reported to play a prominent role in 
chondrocyte dysfunction as a part of OA pathogenesis and disease progression (22). 
Since the OA SBOs are reported to alter the cartilage phenotype, it is possible that 
these alterations in ACCs may occur via MAPK regulation. However, there are no 
studies to date that have explored the role of MAPKs signaling factors in the cell-cell 
interactions of SBOs and ACCs. The present study was to investigate MAPKs 
signaling pathways in the hypertrophic changes of normal ACCs induced by OA 
SBOs using both direct and indirect co-culture systems.   
 
 
 
Methodology 
 
Articular cartilage sample collection and phenotypic determination: Ethics 
approval for this project was granted from the Queensland University of Technology 
and Prince Charles Hospital Ethics Committees and informed consent was given by 
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all patients involved. OA ACCs (n=5) were sourced from the main defective area of 
the medial compartment cartilage showing degenerative changes. The average age of 
OA patients used in this study was 65.20 ± 5.94. Normal ACCs (n=3) were obtained 
from trauma patients, where knee tissue was available. Normal patients were healthy 
adults aged between 53.56 ± 10.76 years old, with no clinical signs or symptoms of 
joint, metabolic or hormonal diseases (osteoporosis), and with no history of 
medication that might affect cartilage or bone metabolism. To eliminate early OA 
symptoms, samples showing any evidence of cartilage changes were excluded. These 
changes included softening of the hyaline articular cartilage; thinning and fibrous 
dislocation; ulcerations of the cartilage; and light sclerosis of the subchondral bone. 
Cartilage was classified according to Mankin score (23) based on saffranin-O and 
H&E histology staining. Chondrocytes from the cartilage tissues were isolated 
following a method described previously (24). Only early passage ACCs (P0 to P2), 
showing a strong expression of type II collagen (COL2) and aggrecan (AGG) were 
used for subsequent experiments.  
 
Subchondral bone sample and phenotypic determination: Bone specimens were 
taken within 5 mm of the subchondral bone plate. OA SBOs (n=5) were sourced from 
the weight bearing sites, where the cartilage was degraded and showed prominent 
subchondral bone erosion and density, from patients with advanced OA and 
undergoing primary total knee replacement surgery. The average age of OA patients 
used in this study was 65.20 ± 5.94. Normal SBOs (n=3) were collected from patients 
undergoing surgery for fracture repair, with no evidence of bone erosion or the 
cartilage degeneration, as judged by criteria established by the American College of 
Rheumatology (25). Normal patients were healthy adults aged 53.56 ± 10.76  years 
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old, with no clinical signs or symptoms of joint, metabolic or hormonal diseases 
(osteoporosis) or taking medication that might affect cartilage or bone metabolism. 
After removing the overlaying cartilage, SBOs were isolated according to a 
methodology described by Beresford (26, 27). Isolated normal and OA SBOs were 
differentiated in the osteogenic medium (supplemented with 10% foetal bovine serum 
(FBS) (In Vitro Technologies, Nobel Park, VIC, Australia), 50 u/mL penicillin, 50 
µg/mL streptomycin, 10nM dexamethasone, 10mM β-glycero-phosphate, 50μg/mL 
ascorbic acid) for the characterization of bone cell phenotype determined by the 
expression of the bone markers of alkaline phosphatase (ALP) and osteocalcin (OC), 
as well as the staining by 1% alizarin red solution after 2 weeks of osteogenic 
induction.  
 
Chondrocyte pellet culture: Cell culture systems known to preserve the chondrocyte 
phenotype were used in the co-culture studies.  2x105 cells of ACCs were resuspended 
in a serum free chondrogenic media (serum-free medium-high glucose DMEM 
(Invitrogen, Mt Waverley, VIC, Australia) supplemented with 10 ng/mL transforming 
growth factor-β3 (Bio Scientific, Gymea, NSW, Australia), 10nM dexamethasone, 50 
mg/mL ascorbic acid, 10 mg/mL sodium pyruvate, 10 mg/mL proline, and an 
insulin+transferrin+selenium supplement (final concentration: 10 µg/mL insulin, 5.5 
µg/mL transferrin, 5 ng/mL sodium selenite, ,0.5 mg/mL bovine serum albumin and 
4.7 µg/mL linoleic acid) and centrifuged at 600 x g for 20 min to form a pellet.  
Pellets were allowed to differentiate for two weeks in 3 dimensional conditions in 15 
mL Falcon tubes, in chondrogenic medium which was replenished every 2 to 3 days. 
After 2 weeks of chondrogenesis ACCs pellets were co-cultured with normal or OA 
SBOs as described below.  
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High density micromass culture: High density micromass droplets were prepared as 
described previously (18). Briefly, following trypsinization the ACCs were 
resuspended in growth media at a final cell density of 2.5×107 cells/mL and spotted as 
10 μL/well droplets in 24 well culture plates and incubated at 37oC for 2 hr to allow 
the cell attachment to the plate.  Micromasses were cultured for 1 week in 
chondrogenic media. After 1 week, micromasses containing ACCs were cultured with 
the conditioned media generated from normal or OA SBOs as described below.  
 
Direct co-culture: ACC pellets were prepared as described above and placed directly 
upon the monolayer of normal or OA SBOs (75,000 cells/well) in the 24 well plates 
and co-cultured for further 2 weeks in the high glucose DMEM supplemented with 
1% FCS, 0.5% glutamine, 50 u/mL penicillin, 50 µg/mL streptomycin 50µM ascorbic 
acid, 10nM dexamethasone, and 10 mM β-glycerophosphate. After 14 days of co-
culture, the ACC pellets were washed three times in PBS and fixed in 4% 
paraformaldehyde for 10 min and stained with 1% alizarin red or 0.5 % alcian blue to 
assess the effect of normal or OA SBOs on ACCs matrix deposition. RNA and protein 
was also extracted from some of the pellets. The culture system selected for this co-
culture study was modified from the previously described protocols of formation of a 
chondro-osseous rudiment in micromass cultures (28).  
 
Indirect co-culture:  Preparation of SBOs conditioned medium (CM): Passage 2, 
SBOs from normal and OA subchondral bone (2.5×105 cells) were cultured in high 
glucose DMEM supplemented with 1% FCS, 0.5% glutamine, 25 units/mL penicillin, 
25 µg/mL streptomycin 50 µM ascorbic acid, 10nM dexamethasone, and 10 mM β-
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glycerophosphate in 25 cm2 flasks for 2 days. The media from these flasks was 
collected and centrifuged at 1000 × g for 15 min and the supernatants were transferred 
to fresh tubes and mixed with an equal volume of fresh (preincubated in 37oC in the 
incubator) media with the same supplements to form CM. During co-culture 
experiments, ACCs micromasses, prepared as described above, were grown for 1 
week in CM from either normal or OA SBOs. The control ACCs were cultured in the 
same above medium composition, which was not incubated with SBOs. Media was 
replenished for every 2 days. At the end of co-culture period, protein and total RNA 
was harvested from the ACCs and some cells were fixed with 4% paraformaldehyde 
and stained with alizarin red and alcian blue to assess extracellular matrix deposition.  
 
Detection of MAP kinase activation:  The MAP kinase mediated cellular 
interactions was evaluated by using the MAP kinase inhibitors SB203580 
(Novabiochem, Alexandria, NSW, Australia) and PD98059 (Novabiochem) for p38 
and ERK1/2 pathway inhibition respectively. ACC micromasses were incubated with 
or without the MAPK inhibitors in CM prepared from normal or OA SBOs. The stock 
solutions of each inhibitor were dissolved in DMSO; the final concentration of DMSO 
not exceeding 0.1% (v/v). An equal amount of DMSO vehicle was added to control 
ACCs. Medium was replenished every 2 days. The optimal concentration for 
inhibition in ACCs was found to be 10 μM for ERK1/2 and 5 μM for p38. At these 
concentrations there was no evidence of cytotoxicity, nor was cell proliferation 
influenced by the addition of the inhibitors. All experiments were performed in 
triplicates.  
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RNA Extraction and Quantitative RT-PCR (qRT-PCR): Total RNA was isolated 
with TRIZOL reagent (Invitogen), DNase treated and column purified using an 
RNeasy Mini Kit (QIAGEN Pty Ltd, VIC, Australia). Complementary DNA was 
synthesized using Superscript III (Invitrogen) from 1µg total RNA following the 
manufacturer’s instructions. PCR primers were designed based on cDNA sequences 
from the NCBI Sequence database using the Primer Express® software and the 
primer specificity were confirmed by BLASTN searches. RT-qPCR was performed 
on an ABI Prism 7000 Thermal Cycler (Applied Biosystems, Scoresby, VIC, 
Australia) with SYBR Green detection reagent. Briefly, 2 µL of cDNA, 20 pmol of 
gene-specific primers and 10 μL of 1x Master Mix were used in a 20 μL reaction 
volume; each sample was performed in duplicates. The thermo cycling conditions 
were as follows: 1 cycle of 10 min at 95°C for activation of the polymerase, 40 cycles 
of 10 sec at 95°C and 1 min at 60°C for amplification. Dissociation curve analysis 
was carried out to verify the absence of primer dimers and/or non-specific PCR 
products. The relative expression of the genes of interest was normalized against 
housekeeping genes of GADPH and 18s.  
 
Western blot: Total protein lysates were harvested by lysing the cells with a lysis 
buffer containing 1 M Tris HCl (pH 8), 5 M NaCl, 20% Triton X140, 0.5 M EDTA 
and a protease inhibitor cocktail (Roche, Castle Hill, Australia). The cell lysate was 
clarified by centrifugation and the protein concentration determined by a 
bicinchoninic acid protein assay (Sigma, Castle Hill, Australia). Ten microgram of 
protein was separated by electrophoresis on a 12 % sodium dodecyl sulfate-
polyacrylamide gel, transferred to a nitrocellulose membrane, and blocked with a 
Tris-Tween buffer containing 5% non-fat milk. The membranes were incubated with 
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primary antibodies against phospho-p38 (1:1000, Genesearch, Arundel, Australia), 
phospho-ERK1/2 (1:2000, Quantum Scientific, Murarrie, Australia) and tubulin (1: 
5000, Quantum Scientific) overnight at 4ºC. After washing the membranes three times 
in TBS-Tween buffer they were incubated with anti-rabbit secondary antibody at 
1:2000 dilutions for 1 hr. The protein bands were visualized using the ECL Plus™ 
Western Blotting Detection Reagents (Amersham Biosciences, Castle Hill, Australia) 
and exposed on X-ray film (Fujifilm, Stafford, Australia). Immunoblots were 
analysed by densitometry using Image J software. 
 
Statistical analysis: Each normal ACC co-cultured with either normal SBOs (n=3) or 
OA SBOs (n=3) and the study was repeated in three normal ACCs. Results were 
presented as a mean ± SD. The relative expression is the mean of three combinations 
of chondrocytes and osteoblasts in the co-culture studies. Repeated measures 
ANOVA with post hoc tests were used to assess statistical significance, where p ≤ 
0.05 was considered significant.  
 
Results 
Expression of chondrogenic and hypertrophic genes in normal and OA ACCs:  
The cell proliferation study indicated that there was no difference in cell numbers 
between normal and OA ACC pellet culture (data not shown). The mRNA expression 
of chondrogenic and hypertrophic marker genes was compared between normal and 
OA ACCs. The expression of CBFA1 (p≤0.05), COL10 (p≤0.05) and ALP (p≤0.05) 
was all significantly upregulated in OA ACCs compared to normal ACCs, whereas 
the expression of COL2 and AGG expression (p≤0.05) was significantly down 
regulated in OA ACCs compared to normal ACCs (Fig 1A). These results indicated 
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that OA ACCs had greater potential to undergo hypertrophic differentiation compared 
to normal ACCs. With respect to MAPK phosphorylation, it was observed that the 
p38 phosphorylation was down regulated in OA ACCs in comparison to normal 
ACCs (Fig 1B). On the other hand ERK1/2 phosphorylation was significantly up 
regulated in OA ACCs compared with normal ACCs (Fig 1C).  
 
Hypertrophic differentiation of normal ACCs in the co-culture with OA SBOs  
Direct co-culture: No difference in the cell proliferation rates was observed in SBOs 
after 14 days culture (data not shown). At day 14 of co-culture GAG matrix 
deposition was lower in the co-culture groups compared to non co-cultured ACCs. 
There was slightly lower staining intensity in the co-culture with OA SBOs compared 
with normal SBOs  (Fig 2A, upper panel). On the other hand, mineralization in the 
ACCs pellets was significantly enhanced in ACCs co-cultured with OA SBOs 
compared to non co-cultured ACCs and ACCs co-cultured with normal SBOs (Fig 
2A, middle panel). The expression of COL2 immunostaining was decreased in the 
co-culture groups compared to non co-cultured ACCs pellets. Furthermore, the 
expression of COL2 in ACCs was significantly decreased in the presence of OA 
SBOs compared to normal SBOs (Fig 2A, lower panel). At the gene expression level, 
cartilage specific genes such as COL2 and AGG were significantly lower in ACCs co-
cultured with OA SBOs compared to ACCs co-cultured with normal SBOs and ACCs 
alone (Fig 2B). These observations were further validated by the mRNA expression 
of hypertrophy and mineralization marker genes in ACCs pellets. The results from 
RT-qPCR indicated that OA SBOs induced a significant upregulation of 
mineralization and hypertrophic markers such as COL10, ALP and CBFA1 compared 
to co-culture group containing normal SBOs and ACC pellets alone (Fig 2C).  
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Indirect co-culture: When ACC micromasses were cultured with normal or OA SBO 
CM, alcian blue staining reveled that cartilage matrix deposition was attenuated by 
both normal and OA SBOs CM; however, the cartilage matrix loss was more 
prominent in the case of OA SBOs CM (Fig 3A, upper panel). Conversely, matrix 
mineralization was greater in ACC micromasses grown for 7 days in OA SBOs CM as 
demonstrated by alizarin red staining (Fig 3A, lower panel). The induction of 
cartilage specific genes COL2 and AGG was significantly downregulated in the 
presence of both normal and OA SBOs CM compared to ACCs cultured alone, 
although this decrease was more prominent in ACCs grown in the presence of OA 
SBOs CM (Fig 3B). By contrast, the expression of cartilage hypertrophy markers 
CBFA1, COL10 and ALP, were significantly upregulated in the presence of OA SBOs 
CM (Fig 3C) compared to both normal SBOs CM and control groups.  
 
Phospho p38 and pERK1/2 kinase signaling pattern in the co-cultured ACCs 
The effect of normal and OA SBOs on the ACCs was assessed with respect to 
alteration of MAPK signaling cascade in both direct and indirect co-culture systems. 
The results showed that the phosphorylation of ERK1/2 was significantly augmented 
when ACCs were co-cultured with OA SBOs, in both the direct and indirect co-
culture models, compared to non co-cultured ACCs and ACCs co-cultured with 
normal SBOs. p38 phosphorylation, on the other hand, was considerably 
downregulated in the ACCs co-cultured with normal SBOs compared to ACCs alone.  
Nonetheless, the co-culture of ACCs with OA SBOs led to a complete attenuation of 
p38 phosphorylation. These results suggest that upregulation of ERK1/2 and 
downregulation of p38 phosphorylation are involved in the interaction between ACCs 
and SBOs, which in turn leading to ACCs hypertrophic changes (Fig 4A-D).  
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Addition of ERK1/2 inhibitor PD98059 reversed the ACCs phenotypic changes 
induced by OA SBOs CM  
Incubation with ERK1/2 inhibitor PD98059 in ACCs cultured with OA SBOs CM 
had the effect of decreasing the phopho-ERK1/2 and increasing the expression of 
phospho-p38 in a concentration dependent manner (Fig 5A). ACCs alone did not 
show significant changes in response to the addition of PD98059, an indication that 
the observed effects were specific to OA SBO CM. RT-qPCR showed that use of 
PD98059 reversed the expression of hypertrophic gene expression of CBFA1, COL10 
and ALP in ACCs micromasses cultured in the presence of OA SBOs CM (Fig 5B). 
By contrast, the expression of COL2 and AGG was upregulated by addition of 
PD98059 (Fig 5C).  
 
Inhibitor of p38, SB203580, induced hypertrophic gene expression in ACCs 
cultured in normal SBOs CM 
Inhibition of the p38 phosphorylation by SB203580 led to reduction of p38 activity 
and activated ERK1/2 phosphorylation in ACCs cultured in normal SBO CM (Fig 
6A). In the presence of SB203580, the hypertrophic markers of CBFA1, COL10, and 
ALP were significantly enhanced, whereas, chondrogenic markers of COL2 and AGG 
were downregulated in ACCs in the presence of normal SBOs CM (Fig 6C&D). 
These results indicate the use of SB203580 could significantly shift of ACCs towards 
a more hypertrophic phenotype. Similar results were also obtained in normal ACCs 
cultured alone (data not shown). 
 
Discussion  
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In this study we have demonstrated the importance of MAPK signaling pathways as 
the means by which OA SBOs induce altered ACCs phenotypic changes, and provide 
some insight into the cross-talk taking place between the p38 and ERK1/2 signaling 
pathways during this pathological interaction process.  
 
It was observed that ACCs isolated from OA patients produced significantly greater 
levels of the CBFA1, COL10 and ALP mRNA when compared to ACCs isolated from 
healthy patients. This finding indicates that the OA ACCs possessed greater potential 
to undergo hypertrophic differentiation, results which corroborate previous work 
comparing normal and OA ACCs (29, 30).  
 
Applying an in vitro indirect co-culture model, Sanchez et al demonstrated that the 
sclerotic OA SBOs decreased cartilage specific gene expression such as SOX9 and 
COL2. They also showed that inhibitors of hypertrophic differentiation such as pTHrP 
and PTH-R were significantly downregulated in ACCs co-cultured with OA SBOs 
(13). These findings are evidence that OA SBOs can decrease the inhibitors of 
hypertrophic differentiation leading to a subsequent mineralized matrix deposition in 
cartilage. In the present study, using both direct and indirect co-culture methods, we 
showed that OA SBOs increased both hypertrophic gene expression and matrix 
mineralization. Interestingly, hypertrophic changes are followed by a simultaneous 
decrease of the chondrocyte specific phenotype. A characteristic change of OA is an 
upregulation of hypertrophy and mineralization related markers (4) and a 
downregulation of chondrocyte specific markers (COL2 and AGG) in articular 
cartilage (31). The observations in our study suggest that the interaction of OA SBOs 
may lead to these typical hypertrophic changes in ACCs. It has been reported that the 
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transition of ACCs to hypertrophic changes contributes to the activation of matrix 
metallo proteinases (MMP), which precedes cartilage degeneration (32, 33), 
indicating that the phenotypic conversion of ACCs to hypertrophy is pathological for 
the health and integrity of articular cartilage leading to its degeneration.  
 
However, the reasons as to why OA SBOs seem to induce these altered ACCs 
phenotype remain unclear; there are nevertheless several potential pathways 
responsible. Both our own studies (data not shown), and that from other groups, have 
demonstrated that OA SBOs produce abnormal levels of osteogenic markers, growth 
factors and cytokines. Specifically, increased production of growth factors such as 
insulin like growth factor (IGF)-1(34), and transforming growth factor (TGF)-β (35) 
are reported in OA SBOs s. Among these factors IGF-1  is implicated in inducing 
cartilage hypertrophic changes in growth plate chondrocytes (36, 37).  In addition, it 
has been reported that OA SBOs produce abnormal levels of cytokines such as 
interleukin (IL)-1 & -6 (35), tumor necrosis factor (TNF) and MMP-13 (38, 39), the  
factors that have the ability to activate a diverse array of signaling pathways in 
cartilage hypertrophy. Therefore, it is possible that the secreted bio-molecules from 
OA SBOs either individually or co-operatively communicate with ACCs there by 
mediating theinducing  phenotype changes of ACCs.  Further studies are required to 
delineate the soluble factors from OA SBOs that are responsible for triggering 
hypertrophic changes of ACCs in OA. 
 
Among signaling factors, the MAPK subtypes ERK1/2 and p38 play a key role in the 
signaling process of chondrocyte cellular differentiation and homeostasis depending 
on the nature of extracellular stimuli (15, 40). This knowledge prompted us to 
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investigate MAPK signaling in the context of what influence normal and OA SBOs 
have on the differentiation of ACCs. This is the first study of its kind to report that 
OA SBOs induce ERK1/2 phosphorylation and suppress p38 phosphorylation in 
ACCs, indicating that the alterations of these pathways accompany ACC pathological 
phenotypic changes. Indeed, we have demonstrated that the basal levels of ERK1/2 
phosphorylation increased and p38 decreased in OA ACCS compared to normal 
ACCs, an indication of the pathological relevance of this pathways in OA 
pathogenesis.  
 
When the influence of ERK1/2 phosphorylation is blocked by an inhibitor, p38 was 
activated in ACCs grown in the presence of OA SBO conditioned media. The 
application of ERK1/2 inhibitor in OA SBOs CM,  reversed ACCs hypertrophy and 
there was a return to the chondrogenic phenotype of ACCs. This observation implies 
that OA SBOs induced altered phenotypic changes in ACCs via a deactivation of p38 
and an activation of the ERK1/2 phosphorylation. This notion was further supported 
by results showing that when p38 was neutralized by an inhibitor in ACCs co-cultured 
with normal SBOs, ERK1/2 phosphorylation was augmented and a weakening of 
chondrogenic gene expression and increase of hypertrophic gene expression was 
observed. Together this data indicates that OA SBOs decrease p38 phosphorylation 
and increase ERK1/2 activity, with a resulting reduced chondrogenic phenotype and 
increased hypertrophic phenotype. MAPKs are regulated at several levels, including 
kinase-kinase and kinase-substrate interactions, and inhibition of cross-talk/output by 
the MAPKs themselves (41, 42). The activities of p38 are primarily governed by 
extensive cross-talk with ERK1/2, a process that involves protein phosphatase, 
resulting in a reciprocal bidirectional equilibrium between ERK1/2 and p38 
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phosphorylation, where an increase in p38 activity suppresses activation of ERK1/2 
and vice versa (43). Such cross-talk appears to play a role in OA SBOs regulated 
ACCs phenotype, the existence of which has been shown in chondrocytes. For 
example, the opposing roles of ERK1/2 and p38 have been demonstrated in 
chondrogenesis regulation (44).  The finding that the ERK1/2 activation increased the 
hypertrophic differentiation in ACCs, are consistent with the study showing the strong 
activation of ERK1/2 pathway in hypertrophic zone of the growth plate (45) (45). 
Furthermore, it has been demonstrated that the inhibition of ERK1/2 delayed 
hypertrophic differentiation in growth plate chondrocytes during endochondral 
ossification (46).  
 
It is possible that components of the p38 and ERK1/2 pathways may interact directly 
in the transcriptional complex. The intermediate p38 and ERK1/2 pathway substrates 
involved in these interaction are not known, but it is interesting that PD98059 (anti 
ERK1/2) significantly reduced the expression of the transcription factor CBFA1, 
whereas SB203580 (anti p38) activated this transcription factor. During early 
skeletogenesis chondrocyte hypertrophy is stimulated through the expression of 
CBFA1 in prehypertrophic chondrocytes, most likely by upregulation of COL10 
expression (47). Continuous expression of CBFA1 in chondrocytes induces 
hypertrophic differentiation and endochondral ossification, suggestive of an important 
role of this transcription factor in triggering hypertrophic changes (48). It is therefore 
possible that OA SBOs induced altered phenotypic changes are triggered in ACCs via 
the activation of MAPK-CBFA1 pathway.  
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Conclusions:  This study demonstrated that OA SBOs could induce the activation of 
ERK 1/2 and deactivation of p38 in ACCs resulting hypertrophic changes of 
chondrocytes.  These data provide an insight into MAPK signaling pathways involved 
in the molecular mechanisms of osteoarthritis pathogenesis, which may have 
significant clinical implications.  
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Legends  
 
Figure 1: Characterization of micromass culture of normal and OA ACCs  
(A) The mRNA expression of chondrogenic and hypertrophic marker genes was 
compared between normal (n=3) and OA ACC (n=5) micromasses after 7 days 
culture in hypertrophic differentiation media containing high glucose DMEM 
supplemented with 1% FCS, 0.5% glutamine, 50 u/mL penicillin, 50 µg/mL 
streptomycin 50µM ascorbic acid, 10nM dexamethasone, and 10 mM β-
glycerophosphate. The expression of CBFA1, COL10 and ALP was significantly up 
regulated in OA ACCs compared to normal ACCs. However, the expression of COL2 
an AGG was significantly decreased in OA ACCs. Results are shown as mean ± SD. 
*: p≤0.05. (B-C) Western blot analysis was performed to determine phosphorylation 
changes of p38 (B) & ERK1/2 (C). Tubulin was used as a loading control. The figures 
are representative of protein bands from three separate experiments. * represents a 
significant difference (p<0.05). 
 
Figure 2: Effects of normal and OA SBOs on ACCs matrix deposition and gene 
expression in direct co-culture.  
(A) Cartilage matrix including GAG stained by alcian blue and COL2 was 
significantly decreased and mineralization matrix stained by Alizarin red was 
significantly increased in ACC pellets co-cultured with OA SBOs. ACC pellets grown 
alone acted as controls (n=3). (B-C) Chondrogenic markers of COL2 and AGG were 
downregulated, but hypertrophic markers of CBFA1, COL10, and ALP were 
significantly upregulated in ACCs co-cultured with OA SBOs. mRNA levels were 
normalized against GAPDH and 18s and the relative expression is presented. Results 
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are shown as mean ± SD from three combination studies of normal ACC pellets co-
cultured with OA SBOs. * represents a significant difference (p<0.05).  
 
Figure 3: Effects of normal and OA SBOs conditioned media (CM) on normal 
ACCs matrix deposition and gene expression in indirect co-culture.  
(A) ACCs were cultured with CM from normal or OA SBOs and control ACC 
micromasses were cultured in non-CM. GAG deposition decreased and matrix 
mineralization increased in the ACCs cultured with OA SBOs CM after 7 days. 
(B&C) Expression levels of COL2 and AGG decreased and CBFA1, COL10, and ALP 
level increased by quantitative PCR after culturing ACC micromasses for 7 days in 
OA SBOs CM. Results are shown as mean ± SD from three combination studies of 
ACCs cultured with CM. * represents a significant difference (p<0.05).   
 
Figure 4: MAPK signaling pattern in the direct and indirect co-cultures of ACCs 
(A) ACC pellets were co-cultured directly with normal or OA SBOs monolayer. After 
14 days the ACCs pellet protein was isolated and increased phospho-ERK1/2 and 
decreased phopho-p38 were noted in the co-culture with OA SBOs. ACC pellets 
cultured alone were used as control. Tubulin was used as a loading control. (B) ACCs 
micromasses were cultured in the presence or absence of CM from normal or OA 
SBOs for 7 days. Increased phospho-ERK1/2 and decreased phopho-p38 were 
detected.  Band density quantification was performed using Image J software for 
phopho-ERK1/2 (D) and phospho-p38 (E). Each value represents a protein bands 
from three separate experiments. The mean ± SD is shown from three combination 
studies of ACC pellets co-cultured with SBOs. * represents a significant difference 
(p<0.05).  
 21
 
Figure 5: Use of PD98059 reversed the expression of hypertrophic genes in ACCs 
induced by OA SBOs conditioned media (CM) (A) ACCs micromasses were 
cultured in CM from OA SBOs with or without the ERK1/2 inhibitor PD98059 at 
different concentrations. After 7 days, total cell protein was isolated from ACCs 
micromasses and phosphorylation changes in ERK1/2 and p38 were measured. 
PD58059 decreased the levels of ERK1/2 in a concentration dependent manner, with 
a co-contaminant increase of p38 levels. (B-C) The mRNA expression of COL2 and 
AGG in ACCs micromasses was enhanced with addition of ERK1/2 inhibitor 
PD98059 upon culturing with OA SBOs CM, but CBFA1, COL10, and ALP mRNA 
was downregulated retrospectively. mRNA levels were normalized against GAPDH 
and 18s and the relative expression is shown. Results were representative of three 
combination studies of ACCs micromasses cultured in CM from OA SBOs. * 
represents a significant difference (p<0.05). 
 
Figure 6: Use of SB203580 induced the expression of hypertrophic genes in   
ACCs cultured with normal SBOs conditioned media (CM).  
(A) ACCs micromasses were cultured in CM from normal SBOs with or without the 
p38 inhibitor, SB203580. After co-culture for 7 days, total cell protein was isolated 
from ACCs and changes to p38 and ERK1/2 phosphorylation was measured. Addition 
of SB203580 in culture media showed inhibitory effect on p38 phosphorylation, but 
enhanced pERK1/2 activity. (B-C) SB203580, decreased the expression of COL2 and 
AGG, but increased CBFA1, COL10, and ALP mRNA level in ACCs micomasses 
after co-culturing with normal SBOs. mRNA levels were normalized against GAPDH 
and 18s and the relative expression is shown. Results were representative of three 
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combination studies of ACCs micromasses cultured in CM from normal SBOs. * 
represents a significant difference (p<0.05). 
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Figure 1: Characterization of micromass culture of normal and OA ACCs  
(A) The mRNA expression of chondrogenic and hypertrophic marker genes was compared between normal (n=3) and OA ACC 
(n=5) micromasses after 7 days culture in hypertrophic differentiation media containing high glucose DMEM supplemented with 
1% FCS, 0.5% glutamine, 50 u/L penicillin, 50 µg/mL streptomycin 50µM ascorbic acid, 10nM dexamethasone, and 10 mM β-
glycerophosphate. The expression of CBFA1, COL10 and ALP was significantly up regulated in OA ACCs compared to normal 
ACCs. However, the expression of COL2 an AGG was significantly decreased in OA ACCs. Results are shown as mean ± SD. *: 
p≤0.05. (B-C) Western blot analysis was performed to determine phosphorylation changes of p38 (B) & ERK1/2 (C). Tubulin 
was used as a loading control. The figures are representative of protein bands from three separate experiments. * represents a 
significant difference (p<0.05). 
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Figure 2: Effects of normal and OA SBOs on ACCs matrix deposition and gene expression in direct co-culture.  
(A) GAG stained by alcian blue and COL2 was significantly decreased and mineralization matrix stained by Alizarin red was 
significantly increased in ACC pellets co-cultured with OA SBOs. ACC pellets grown alone acted as controls (n=3). (B-C) 
Chondrogenic markers of COL2 and AGG were downregulated and hypertrophic markers of CBFA1, COL10, and ALP were 
significantly upregulated in ACC pellets co-cultured with OA SBOs .mRNA levels were normalized against GAPDH and 18s 
and the relative expression is presented. Results are shown as mean ± SD from three combination studies of normal ACC pellets 
co-cultured with OA SBOs. * represents a significant difference (p<0.05).  
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Figure 3: Effects of normal and OA SBOs conditioned media (CM) on normal ACCs matrix deposition and gene 
expression in indirect co-culture.  
(A) ACCs were cultured with CM from normal or OA SBOs and control ACC micromasses were cultured in non-CM. GAG 
deposition decreased and matrix mineralization increased in the ACCs cultured with OA SBOs CM after 7 days. (B&C) 
Expression levels of COL2 and AGG decreased and CBFA1, COL10, and ALP level increased by quantitative PCR after culturing 
ACC micromasses for 7 days in OA SBOs CM. Results are shown as mean ± SD from three combination studies of ACCs 
cultured with CM. * represents a significant difference (p<0.05).   
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Figure 4: MAPK signaling pattern in the direct and indirect co-cultures of ACCs 
(A) ACC pellets were co-cultured directly with normal or OA SBOs monolayer. After 14 days the ACCs pellet protein was 
isolated and increased phospho-ERK1/2 and decreased phopho-p38 were noted in the co-culture with OA SBOs. ACC pellets 
cultured alone were used as control. Tubulin was used as a loading control. (B) ACCs micromasses were cultured in the presence 
or absence of CM from normal or OA SBOs for 7 days. Increased phospho-ERK1/2 and decreased phopho-p38 were detected.  
Band density quantification was performed using Image J software for phopho-ERK1/2 (D) and phospho-p38 (E). Each value 
represents a protein bands from three separate experiments. The mean ± SD is shown from three combination studies of ACC 
pellets co-cultured with SBOs. * represents a significant difference (p<0.05).  
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 Figure 5: Use of PD98059 reversed the expression of hypertrophic gene in ACCs induced by OA SBOs conditioned media 
(CM) . (A) ACCs micromasses were cultured in CM from OA SBOs with or without the ERK1/2 inhibitor PD98059 at different 
concentrations. After 7 days, total cell protein was isolated from ACCs micromasses and phosphorylation changes in ERK1/2 
and p38 were measured. PD58059 decreased the levels of ERK1/2 in a concentration dependent manner. (B-C) The mRNA 
expression of COL2 and AGG in ACCs micromasses was enhanced with addition of ERK1/2 inhibitor PD98059 upon culturing 
with OA SBOs CM, but CBFA1, COL10, and ALP mRNA was downregulated retrospectively. mRNA levels were normalized 
against GAPDH and 18s and the relative expression is shown. Results were representative of three combination studies of ACCs 
micromasses cultured in CM from OA SBOs. * represents a significant difference (p<0.05). 
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Figure 6: Use of SB203580 induced the expression of hypertrophic gene in  ACCs cultured with normal SBOs conditioned 
media (CM).  
(A) ACCs micromasses were cultured in CM from normal SBOs with or without the p38 inhibitor, SB203580. After co-culture 
for 7 days, total cell protein was isolated from ACCs and changes to p38 and ERK1/2 phosphorylation was measured. Addition 
of SB203580 in culture media inhibited p38 phosphorylation. (B-C) SB203580 decreased the expression of COL2 and AGG, but 
increased CBFA1, COL10, and ALP mRNA level in ACCs micomasses after co-culturing with normal SBOs. mRNA levels 
were normalized against GAPDH and 18s and the relative expression is shown. Results were representative of three combination 
studies of ACCs micromasses cultured in CM from normal SBOs. * represents a significant difference (p<0.05). 
 
 
